ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,427.13
      -2.31%
      US Tech 100
      18,493.20
      -0.23%
      Dow Jones
      39,853.87
      0.00%
      Brent Oil
      79.655
      -1.34%
      Bitcoin
      64,145.92
      -1.88%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Inozyme Pharma Inc (INZY) Quote

      Inozyme Pharma Inc

      Inozyme Pharma Inc (INZY)

      NASDAQ
      5.70
      0.03
      (0.53%)
      Closed July 24 4:00PM
      Delayed by 15 minutes
      5.70
      0.00
      ( 0.00% )
      Pre Market: 7:00AM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      5.70
      Bid
      5.06
      Ask
      6.28
      Volume
      -
      0.00 Day's Range 0.00
      2.689 52 Week Range 7.795
      Market Cap
      352.576M
      Previous Close
      5.70
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      332,683
      Shares Outstanding
      61,855,509
      Dividend Yield
      -
      PE Ratio
      -4.95
      Earnings Per Share (EPS)
      -1.15
      Revenue
      -
      Net Profit
      -71.17M

      About Inozyme Pharma Inc

      Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.inozyme.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $5.70. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 2.689 to $ 7.795.

      Inozyme Pharma currently has 61,855,509 shares outstanding. The market capitalization of Inozyme Pharma is $352.58 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -4.95.

      INZY Latest News

      More News

      Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

      BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

      July 02 2024
      GlobeNewswire Inc.

      Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

      BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

      June 21 2024
      GlobeNewswire Inc.

      Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

      BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

      May 30 2024
      GlobeNewswire Inc.

      Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

      BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

      May 23 2024
      GlobeNewswire Inc.

      Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

      BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

      May 08 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 07 2024
      Edgar (US Regulatory)

      Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

      - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a...

      May 07 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.010.1757469244295.695.865.20241868545.50619814CS
      41.2728.66817155764.435.864.323151054.94155635CS
      121.0221.79487179494.685.864.243326834.72415452CS
      261.1324.72647702414.577.7954.185152635.47668883CS
      52-0.55-8.86.257.7952.6895248524.87510333CS
      156-13.33-70.047293746719.0319.460.9914282834.48926793CS
      260-12.23-68.20970440617.9331.64990.9913363955.33524318CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PBMPsyence Biomedical Ltd
      $ 1.04
      (165.71%)
      		14.81M
      TIVCTivic Health Systems Inc
      $ 0.5173
      (69.06%)
      		27.29M
      MIRAMIRA Pharmaceuticals Inc
      $ 3.40
      (44.07%)
      		4.07M
      CEROCERo Therapeutics Holdings Inc
      $ 0.272
      (28.91%)
      		18.04M
      NIUNiu Technologies
      $ 2.34
      (23.16%)
      		4
      TWOU2U Inc
      $ 1.24
      (-69.90%)
      		187.83k
      MXLMaxLinear Inc
      $ 17.03
      (-23.60%)
      		18.72k
      RGCRegencell Bioscience Holdings Ltd
      $ 11.20
      (-17.04%)
      		10.44k
      IROQIF Bancorp Inc
      $ 14.44
      (-16.53%)
      		1.22k
      OSTOstin Technology Group Company Ltd
      $ 0.37
      (-15.91%)
      		2.32k
      TIVCTivic Health Systems Inc
      $ 0.5173
      (69.06%)
      		27.29M
      CEROCERo Therapeutics Holdings Inc
      $ 0.272
      (28.91%)
      		18.04M
      PBMPsyence Biomedical Ltd
      $ 1.04
      (165.71%)
      		14.81M
      SLNASelina Hospitality PLC
      $ 0.0433
      (-5.25%)
      		8.25M
      SQQQProShares UltraPro Short QQQ
      $ 9.105
      (0.50%)
      		6.3M

      INZY Discussion

      View Posts
      AJ Freely AJ Freely 12 months ago
      $INZY - 👆Up 7% Pre-Market/ Current Price $5.12
      Pivotal bioVenture Partners Fund I, L.P purchases
      835k shares equal to $4m investment
      👍️0
      Monksdream Monksdream 1 year ago
      INZY new 52 week high
      👍️0
      INFINITI INFINITI 1 year ago
      Loading
      👍️0
      Jess070283 Jess070283 1 year ago
      Have a feeling this about to squeeze into a halt soon…..
      👍️0
      tj9938 tj9938 2 years ago
      Great week so far. Gotta keep it movin.
      👍️0
      tj9938 tj9938 2 years ago
      Quietest board out there
      👍️0
      ErnieBilco ErnieBilco 2 years ago
      Grabbed a starter here today
      👍️0
      crudeoil24 crudeoil24 2 years ago
      INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

      (i) Deep Track Capital, LP

      (ii) Deep Track Biotechnology Master Fund, Ltd.

      (iii) David Kroin

      INZY
      👍️0
      tw0122 tw0122 2 years ago
      I like the BioXc chart looks better. Thanks for all the good insight.
      👍️0
      crudeoil24 crudeoil24 2 years ago
      The offering is expected to close on or about April 19, 2022
      👍️0
      tw0122 tw0122 2 years ago
      This analyst know about the offering?
      Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
      👍️0
      crudeoil24 crudeoil24 2 years ago
      PT > 33.00
      👍️0
      crudeoil24 crudeoil24 2 years ago
      H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
      👍️0

      Your Recent History

      NASDAQ
      INZY
      Inozyme Pharma
      BIT
      S31842
      Societe Generale Effekten
      Delayed Upgrade Clock